Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01334996 · ClinicalTrials.gov registry record
Use of Tamoxifen in Systemic Mastocytosis
A clinical trial of Systemic Mastocytosis, sponsored by Mayo Clinic.
- Completed
- Registry status
- 1
- Enrollment target
- 1
- Study location
NCT01334996: Completed study of Systemic Mastocytosis, sponsored by Mayo Clinic.
NCT01334996 is a study of Systemic Mastocytosis that has completed, run by Mayo Clinic. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01334996, a study of Systemic Mastocytosis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine will be excluded until these medications have been stopped.
Primary Outcome
up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40mg/day and the duration of treatment will be for one year.
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2005-02 |
| Est. Completion | 2019-08-28 |
What the finished NCT01334996 record still lists
NCT01334996 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 1 condition, with Systemic Mastocytosis appearing as the primary indexed condition, and to 0 interventions.
NCT01334996 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01334996 about?
NCT01334996 is a clinical study titled "Use of Tamoxifen in Systemic Mastocytosis". In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release sym...
What is the current status of trial NCT01334996?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2005-02. Estimated completion is 2019-08-28.
What conditions does trial NCT01334996 study?
This clinical trial studies the following conditions: Systemic Mastocytosis.
Who is sponsoring clinical trial NCT01334996?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01334996 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Mastocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia